Intellectus Partners LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 47.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 21,429 shares of the biopharmaceutical company's stock after selling 19,330 shares during the quarter. Intellectus Partners LLC's holdings in Gilead Sciences were worth $1,797,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares during the period. Capital World Investors grew its stake in Gilead Sciences by 1.4% during the 1st quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company's stock worth $6,189,435,000 after buying an additional 1,133,281 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Gilead Sciences by 2.7% during the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company's stock valued at $4,486,296,000 after acquiring an additional 1,589,240 shares in the last quarter. Legal & General Group Plc raised its position in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Gilead Sciences by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 10,412,413 shares of the biopharmaceutical company's stock worth $714,421,000 after purchasing an additional 268,208 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Activity
In other news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
GILD has been the subject of a number of research analyst reports. BMO Capital Markets raised their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Robert W. Baird boosted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Truist Financial raised their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Finally, Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $93.86.
Check Out Our Latest Analysis on GILD
Gilead Sciences Trading Down 4.0 %
Shares of GILD stock traded down $3.71 during trading hours on Friday, hitting $88.40. The company had a trading volume of 11,453,875 shares, compared to its average volume of 7,102,436. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 0.82. The company's fifty day moving average is $86.49 and its 200 day moving average is $75.81. The stock has a market capitalization of $110.17 billion, a PE ratio of 1,007.67, a price-to-earnings-growth ratio of 2.85 and a beta of 0.17.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. The business's quarterly revenue was up 7.0% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 4.39 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.48%. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
